A Phase 1 Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
Latest Information Update: 16 Jan 2026
At a glance
- Drugs TER 1754 (Primary)
- Indications Hereditary haemorrhagic telangiectasia
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Terremoto Biosciences
Most Recent Events
- 08 Jan 2026 Status changed from not yet recruiting to recruiting.
- 05 Dec 2025 New trial record